Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30, 2025 and ...
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE ... and an anti-CD38 monoclonal antibody (Xd). For the treatment ...
President Trump and China's Xi Jinping for the first time on Friday both publicly addressed more details of their emerging tariff and trade truce agreed to in South Korea. Trump on Friday floated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback